**Supplementary Table S3. Phase II best overall response according to RECIST and mRECIST by central independent review.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Treatment Group | | | | | | | |
|  | Nintedanib, 200 mg bid (n = 63) | | | | Sorafenib, 400 mg bid (n = 32) | | | |
| Best Response | No. | | % | | No. | | % | |
| RECIST | | | | | | | | |
| Disease control | | 43 | | 68.3 | | 27 | | 84.4 |
| Objective  response | | 4 | | 6.3 | | 1 | | 3.1 |
| Complete  response | | 2 | | 3.2 | | 0 | | 0 |
| Partial  response | | 2 | | 3.2 | | 1 | | 3.1 |
| Stable  disease | | 39 | | 61.9 | | 26 | | 81.3 |
| Progressive disease | | 17 | | 27.0 | | 5 | | 15.6 |
| Not evaluable | | 2 | | 3.2 | | 0 | | 0 |
| Unknown | | 1 | | 1.6 | | 0 | | 0 |
| mRECIST | | | | | | | | |
| Disease control | | 45 | | 71.4 | | 27 | | 84.4 |
| Objective  response | | 9 | | 14.3 | | 6 | | 18.8 |
| Complete  response | | 2 | | 3.2 | | 0 | | 0 |
| Partial  response | | 7 | | 11.1 | | 6 | | 18.8 |
| Stable disease | | 36 | | 57.1 | | 21 | | 65.6 |
| Progressive disease | | 15 | | 23.8 | | 5 | | 15.6 |
| Not evaluable | | 2 | | 3.2 | | 0 | | 0 |
| Unknown | | 1 | | 1.6 | | 0 | | 0 |

RECIST, Response Evaluation Criteria in Solid Tumours; mRECIST, modified RECIST.